Aim of this study was to explore the effect of bivalirudin on coagulation function with the treatment of percutaneous coronary intervention (PCI) in male coronary heart disease (CHD) patients. There were 90 male CHD cases treated with PCIas study object and were randomly divided into bivalirudin and unfractionated heparin group (n=45). Unfractionated heparin group patients were given unfractionated heparin and bivalirudin group cases were treated with bivalirudin. Activated clotting time (ACT), thrombin time (TT), prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (Fib), platelet count (PLT) were determined and the major adverse cardiovascular events (MACCE) were observed in two group patients. There was no significant (p<0.05) difference with ACT, TT, PT, PLT, APTT and Fib between the two groups before and after 6h, 24h and 72h of operation. The incidence of stent thrombosis and general bleeding with in 24h after PCI in bivalirudin group was lower than in heparin group. After 13 months of follow-up, there was no significant (p<0.05) difference in the incidence of MACCE between the two groups. Compared with the treatment of unfractionated heparin in CHD patients after PCI in 24h, the bivalirudin had more remarkable effect, such as rapid onset, short half-life, lower incidence of thrombosis and bleeding.